← 返回

淋巴瘤中的肿瘤免疫微环境:聚焦表观遗传学

英文原题:Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.

查看英文原题

Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.

PubMed 2022/03/13(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

淋巴瘤是一种起源于B或T淋巴细胞或NK 细胞的肿瘤,以克隆性淋巴增殖为特征。该肿瘤包含一组多样且异质的恶性肿瘤,具有不同的临床、组织病理学和分子特征。尽管淋巴瘤治疗取得了进展,但复发/难治性疾病患者的临床结局仍然很差。因此,需要更深入地了解淋巴瘤的分子发病机制和肿瘤进展。表观遗传改变有助于癌症的发生、进展和耐药。事实上,在过去十年中,已在淋巴瘤中发现了表观遗传机制的失调,而对表观遗传异常的认识促成了淋巴瘤肿瘤中有前景的表观遗传治疗领域的出现。然而,淋巴瘤中的表观遗传异常不仅见于肿瘤细胞,也见于肿瘤微环境中的细胞,如免疫细胞。尽管淋巴瘤细胞中的表观遗传失调正在被深入研究,但关于影响淋巴瘤肿瘤微环境中免疫细胞功能的表观遗传机制的研究仍然有限。因此,本综述试图对影响淋巴瘤细胞和肿瘤内浸润免疫细胞的表观遗传改变,以及它们之间的表观遗传串扰进行总体概述。

展开英文摘要原文

Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. This tumor comprises a diverse and heterogeneous group of malignancies with distinct clinical, histopathological, and molecular characteristics. Despite advances in lymphoma treatment, clinical outcomes of patients with relapsed or refractory disease remain poor.

Thus, a deeper understanding of molecular pathogenesis and tumor progression of lymphoma is required. Epigenetic alterations contribute to cancer initiation, progression, and drug resistance. In fact, over the past decade, dysregulation of epigenetic mechanisms has been identified in lymphomas, and the knowledge of the epigenetic aberrations has led to the emergence of the promising epigenetic therapy field in lymphoma tumors.

However, epigenetic aberrations in lymphoma not only have been found in tumor cells, but also in cells from the tumor microenvironment, such as immune cells. Whereas the epigenetic dysregulation in lymphoma cells is being intensively investigated, there are limited studies regarding the epigenetic mechanisms that affect the functions of immune cells from the tumor microenvironment in lymphoma.

Therefore, this review tries to provide a general overview of epigenetic alterations that affect both lymphoma cells and infiltrating immune cells within the tumor, as well as the epigenetic cross-talk between them.

论文信息

作者
García-Domínguez DJ、Hontecillas-Prieto L、Palazón-Carrión N、Jiménez-Cortegana C、Sánchez-Margalet V、de la Cruz-Merino L
第一作者单位
Clinical Laboratory, Department of Medical Biochemistry and Molecular Biology, School of Medicine, University of Seville, Virgen Macarena University Hospital, 41009 Seville, Spain.Spain
通讯作者单位
Oncology Service, Virgen Macarena University Hospital, Department of Medicines, School of Medicine, University of Seville, 41009 Seville, Spain.Spain
文献类型
综述
期刊
Cancers2022 Mar 13
原文标识
PubMed 35326620 · DOI 10.3390/cancers14061469